Friday, 15 Feb 2019

You are here

Knee Arthroscopic Surgeries on the Decline

A JAMA Internal Medicine report has shown that the rate of arthroscopic surgery has significantly declined, in an era when arthroplasty and the incidence of osteoarthritis (OA) has increased. (Citation source http://bit.ly/2DtpeUp)

The analysis was undertaken as numerous studies have failed to show significant long-term benefits when arthroscopy was used to manage knee pain, meniscal tears and knee OA.

Researchers examined data on all surgeries done on patients 18 and older in Florida from 2002 to 2015.

During this era, there were a total of 868,482 arthroscopic knee procedures and an overall decline in arthroscopic operations of 23%, even moreso after 2008.

In 2002, the knee arthroscopy rate in Florida was 449 procedures per 100,000 adults. By 2015 this fell to 345 procedures per 100,000 adults.  During this timespan, overall knee arthroplastly increased.

The sharper declines after 2008 follow publication of another major study that failed to show a different in outcomes between arthroscopic surgery and medical management. 

 

 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Opioid Use in Osteoarthritis Varies by State

A study in Arthritis & Rheumatology shows that there is substantial statewide variation in rates of treatment with long‐term opioid therapy in osteoarthritis - not fully explained by differences in access to healthcare providers, varying case‐mix, or state‐level policies.

Vertebroplasty and Kyphoplasty Shown to Be Ineffective

There are approximately 750,000 new vertebral compression fractures each year in the United States, with resultant acute and chronic back pain in over one‐third of patients with vertebral fractures (VF).  Both percutaneous vertebroplasty or balloon kyphoplasty have been advocated as useful means of restoring vertebral height and strength capable of reducing pain in symptomatic patients.

FDA Panel Backs Approval of Romosuzumab for Osteoporosis

The US Food and Drug Administration’s advisory committee on Bone, Reproductive and Urologic Drugs voted Wednesday in favor of approving Amgen’s osteoporosis anti-sclerostin drug, romosozumab (Evenity) for use women with postmenopausal osteoporosis. 

Reuters reports that the panel voted 16-1 in favor of the monthly injection developed jointly by UCB.

Heberden’s Nodes Predict Knee OA Progression

Hand and knee osteoarthritis are considered to be clinically and pathogenically different and distinct, but a new study suggests that Heberden's nodes (HNs) can predict MRI‐based knee osteoarthritis (OA) progression.

An NIH study of 575 subjects included clinical examination with evaluation of HNs at baseline and knee MRI at baseline and 24‐month.

NEJM Review - Glucocorticoid-Induced Osteoporosis

Lenore Buckley and Mary Humphrey have published a nice review of glucocorticoid-induced osteoporosis (GIOP) in the NEJM.